PD-1/PD-L1 checkpoint blockadeReduction in tumor burden.Adoptive iNKT cell therapy and IL-6Ra+ NK cell ablationReduction in obesity, hyperlipidemia and leptin production, and upregulation of anti-inflammatory cytokines. Potential improved treatment response when combining checkpoint blockade with adoptive NK cell therapy. Here, LEP is linked to hyperlipidemia.